PPARA and obesity disorder: The potentiation of β3-adrenergic stimulatory effects by the natural cardioprotective PPARα agonist OEA might also help to lower the effective dose of the β3-adrenergic agonist, reducing the unwanted cardiovascular effects of this class of anti-obesity agent.